BIVI Logo

BioVie Inc. (BIVI) 

NASDAQ
Market Cap
$54.37M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
286 of 775
Rank in Industry
165 of 433

Largest Insider Buys in Sector

BIVI Stock Price History Chart

BIVI Stock Performance

About BioVie Inc.

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in …

Insider Activity of BioVie Inc.

Over the last 12 months, insiders at BioVie Inc. have bought $27,800 and sold $127,899 worth of BioVie Inc. stock.

On average, over the past 5 years, insiders at BioVie Inc. have bought $158,007 and sold $176,352 worth of stock each year.

Highest buying activity among insiders over the last 12 months: DO CUONG V (President & CEO) — $27,800.

The last purchase of 10,000 shares for transaction amount of $10,000 was made by DO CUONG V (President & CEO) on 2024‑03‑04.

List of Insider Buy and Sell Transactions, BioVie Inc.

2024-03-04PurchasePresident & CEO
10,000
0.0236%
$1.00$10,000-58.83%
2023-12-01Saledirector
75,680
0.2029%
$1.69$127,899-71.22%
2023-11-30PurchasePresident & CEO
10,000
0.0263%
$1.78$17,800-73.11%
2023-09-05Saledirector
8,560
0.023%
$3.05$26,108-70.38%
2023-08-22Saledirector
10,805
0.0289%
$3.50$37,827-70.15%
2023-06-07Saledirector
5,984
0.017%
$5.81$34,782-69.90%
2023-05-22Saledirector
5,000
0.0137%
$6.50$32,506-54.90%
2023-03-28Saledirector
7,613
0.0213%
$8.52$64,870-59.33%
2023-03-27Saledirector
3,371
0.0096%
$8.52$28,711-58.32%
2021-12-07PurchaseCFO
2,000
0.0084%
$5.40$10,798-38.99%
2020-11-03Purchasedirector
2,430
0.0171%
$7.95$19,319+78.22%
2020-10-30Purchasedirector
2,570
0.0185%
$7.97$20,483+81.68%
2020-10-21Purchasedirector
5,000
0.0362%
$9.19$45,950+58.95%
2020-10-15Purchasedirector
15,100
0.1065%
$10.10$152,517+40.72%
2020-10-09Purchasedirector
282
0.002%
$9.61$2,710+50.83%
2020-10-07Purchasedirector
4,718
0.0343%
$9.42$44,444+55.36%
2020-09-22Purchasedirector
15,000
0.263%
$10.00$150,000+51.62%

Insider Historical Profitability

47.3%
DO CUONG VPresident & CEO
435854
2.453%
$3.0620
GORLIN STEVEdirector
46358
0.2609%
$3.0672+59.63%
KIM JOANNE WENDYCFO
2000
0.0113%
$3.0610<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Altium Capital Management Lp$1.59M4.933.01MNew+$1.59M0.19
SABBY MANAGEMENT LLC$364,277.001.13689,135New+$364,277.000.15
The Vanguard Group$340,722.001.05644,575+83.2%+$154,734.28<0.0001
Cvi Holdings Llc$317,106.000.98599,897New+$317,106.000.33
Renaissance Technologies$184,000.000.57347,400New+$184,000.00<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.